Who Can Afford Personalized Gene Editing? 🧬

For some genetic diseases, treatments tailored to a person's biology may already be technically possible. But the cost of developing and delivering them puts them beyond most patients' reach. Dr. Trevor Martin, co-founder and CEO of Mammoth Biosciences, explains why scaling genetic medicine is such a major challenge. Conditions like sickle cell disease affect populations with limited access to expensive therapies, raising questions about how to make these treatments affordable without overwhelming healthcare systems. Watch the full episode! #GeneEditing #PersonalizedMedicine #CRISPR #GeneticMe